-
Something wrong with this record ?
Newly Developed Drugs for Alzheimer's Disease in Relation to Energy Metabolism, Cholinergic and Monoaminergic Neurotransmission
J. Korábečný, E. Nepovimová, T. Cikánková, K. Špilovská, L. Vašková, E. Mezeiová, K. Kuča, J. Hroudová,
Language English Country United States
Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review
Persistent link
https://www.medvik.cz/link/bmc19013138
- MeSH
- Acetylcholine metabolism MeSH
- Alzheimer Disease drug therapy metabolism MeSH
- Biogenic Monoamines metabolism MeSH
- Energy Metabolism drug effects MeSH
- Central Nervous System Agents chemistry pharmacology therapeutic use MeSH
- Humans MeSH
- Synaptic Transmission drug effects physiology MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Research Support, N.I.H., Extramural MeSH
Current options for Alzheimer's disease (AD) treatment are based on administration of cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and/or memantine, acting as an N-methyl-D-aspartate (NMDA). Therapeutic approaches vary and include novel cholinesterase inhibitors, modulators of NMDA receptors, monoamine oxidase (MAO) inhibitors, immunotherapeutics, modulators of mitochondrial permeability transition pores (mPTP), amyloid-beta binding alcohol dehydrogenase (ABAD) modulators, antioxidant agents, etc. The novel trends of AD therapy are focused on multiple targeted ligands, where mostly ChE inhibition is combined with additional biological properties, positively affecting neuronal energy metabolism as well as mitochondrial functions, and possessing antioxidant properties. The present review summarizes newly developed drugs targeting cholinesterase and MAO, as well as drugs affecting mitochondrial functions.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19013138
- 003
- CZ-PrNML
- 005
- 20221014094907.0
- 007
- ta
- 008
- 190405s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.neuroscience.2017.06.034 $2 doi
- 035 __
- $a (PubMed)28673719
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Korábečný, Jan $u Biomedical Research Centre, University Hospital Hradec Kralové, Sokolská 581, 500 05 Hradec Králové, Czech Republic; National Institute of Mental Health, Topolová 748, 250 67 Klecany, Czech Republic.
- 245 10
- $a Newly Developed Drugs for Alzheimer's Disease in Relation to Energy Metabolism, Cholinergic and Monoaminergic Neurotransmission / $c J. Korábečný, E. Nepovimová, T. Cikánková, K. Špilovská, L. Vašková, E. Mezeiová, K. Kuča, J. Hroudová,
- 520 9_
- $a Current options for Alzheimer's disease (AD) treatment are based on administration of cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and/or memantine, acting as an N-methyl-D-aspartate (NMDA). Therapeutic approaches vary and include novel cholinesterase inhibitors, modulators of NMDA receptors, monoamine oxidase (MAO) inhibitors, immunotherapeutics, modulators of mitochondrial permeability transition pores (mPTP), amyloid-beta binding alcohol dehydrogenase (ABAD) modulators, antioxidant agents, etc. The novel trends of AD therapy are focused on multiple targeted ligands, where mostly ChE inhibition is combined with additional biological properties, positively affecting neuronal energy metabolism as well as mitochondrial functions, and possessing antioxidant properties. The present review summarizes newly developed drugs targeting cholinesterase and MAO, as well as drugs affecting mitochondrial functions.
- 650 _2
- $a acetylcholin $x metabolismus $7 D000109
- 650 _2
- $a Alzheimerova nemoc $x farmakoterapie $x metabolismus $7 D000544
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a biogenní monoaminy $x metabolismus $7 D015306
- 650 _2
- $a látky ovlivňující centrální nervový systém $x chemie $x farmakologie $x terapeutické užití $7 D002491
- 650 _2
- $a energetický metabolismus $x účinky léků $7 D004734
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nervový přenos $x účinky léků $x fyziologie $7 D009435
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Nepovímová, Eugenie $u Biomedical Research Centre, University Hospital Hradec Kralové, Sokolská 581, 500 05 Hradec Králové, Czech Republic; Department of Psychiatry, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 11, 120 00 Prague 2, Czech Republic; Department of Chemistry, Faculty of Science, University of Hradec Králové, Rokitanského 62, 500 03 Hradec Králové, Czech Republic. $7 xx0224758
- 700 1_
- $a Cikánková, Tereza, $u Department of Psychiatry, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 11, 120 00 Prague 2, Czech Republic. $d 1986- $7 xx0268197
- 700 1_
- $a Špilovská, Katarína $u National Institute of Mental Health, Topolová 748, 250 67 Klecany, Czech Republic; Department of Psychiatry, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 11, 120 00 Prague 2, Czech Republic; Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, Třebešská 1575, 500 01 Hradec Králové, Czech Republic.
- 700 1_
- $a Vašková, Lucie $u Department of Psychiatry, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 11, 120 00 Prague 2, Czech Republic; Department of Chemistry, Faculty of Science, University of Hradec Králové, Rokitanského 62, 500 03 Hradec Králové, Czech Republic.
- 700 1_
- $a Mezeiová, Eva $u Biomedical Research Centre, University Hospital Hradec Kralové, Sokolská 581, 500 05 Hradec Králové, Czech Republic; National Institute of Mental Health, Topolová 748, 250 67 Klecany, Czech Republic; Department of Psychiatry, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 11, 120 00 Prague 2, Czech Republic. $7 xx0277560
- 700 1_
- $a Kuča, Kamil $u Biomedical Research Centre, University Hospital Hradec Kralové, Sokolská 581, 500 05 Hradec Králové, Czech Republic; Department of Chemistry, Faculty of Science, University of Hradec Králové, Rokitanského 62, 500 03 Hradec Králové, Czech Republic.
- 700 1_
- $a Hroudová, Jana $u Department of Psychiatry, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 11, 120 00 Prague 2, Czech Republic; Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Albertov 4, 128 00 Prague 2, Czech Republic. Electronic address: hroudova.jana@gmail.com.
- 773 0_
- $w MED00003505 $t Neuroscience $x 1873-7544 $g Roč. 370, č. - (2018), s. 191-206
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28673719 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20221014094859 $b ABA008
- 999 __
- $a ok $b bmc $g 1392448 $s 1051443
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 370 $c - $d 191-206 $e 20170701 $i 1873-7544 $m Neuroscience $n Neuroscience $x MED00003505
- LZP __
- $a Pubmed-20190405
